Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures

Phytomedicine

Volumn 19, Issue 8-9, 2012, Pages 819-824

  Moldzio, Rudolf ^a   Pacher, Thomas ^a   Krewenka, Christopher ^a   Kranner, Barbara ^a   Novak, Johannes ^a   Duvigneau, Johanna Catharina ^a   Rausch, Wolf Dieter ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cannabinoids; Cannabis sativa; Mesencephalic culture; MPP+; Neuroprotection

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,1 DIPHENYL 2 PICRYLHYDRAZYL; CANNABIDIOL; DRONABINOL; TETRAHYDROCANNABINOLIC ACID; TROLOX C; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL COUNT; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MESENCEPHALON; MOUSE; NERVE FIBER GROWTH; NONHUMAN; OXIDATIVE STRESS; PERIKARYON; PRIORITY JOURNAL;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIOXIDANTS; CANNABIDIOL; CANNABIS; CELLS, CULTURED; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; FREE RADICAL SCAVENGERS; MESENCEPHALON; MICE; NEUROPROTECTIVE AGENTS; PREGNANCY; TETRAHYDROCANNABINOL; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; CANNABIS SATIVA; MURINAE; MUS;

EID: 84861812571     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2012.04.002     Document Type: Article

References (28)

1. S.O. Alozie, B.R. Martin, L.S. Harris, and W.L. Dewey 3H-delta 9-tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain Pharmacology, Biochemistry, and Behavior 12 1980 217 221
2. A.J. Brown Novel cannabinoid receptors British Journal of Pharmacology 152 2007 567 575
3. X. Cao, L. Liang, J.R. Hadcock, P.A. Iredale, D.A. Griffith, F.S. Menniti, S. Factor, J.T. Greenamyre, and S.M. Papa Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys Journal of Pharmacology and Experimental Therapeutics 323 2007 318 326
4. B.S. Choi, H.S. Song, H.R. Kim, T.W. Park, T.D. Kim, B.J. Cho, C.J. Kim, and S.S. Sim Effect of coenzyme Q10 on cutaneous healing in skin-incised mice Archives of Pharmacal Research 32 2009 907 913
5. S. Deiana, A. Watanabe, Y. Yamasaki, N. Amada, M. Arthur, S. Fleming, H. Woodcock, P. Dorward, B. Pigliacampo, S. Close, B. Platt, and Riedel Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour Psychopharmacology 219 2011 859 873
6. I. Diaz-Laviada, and L. Ruiz-Llorente Signal transduction activated by cannabinoid receptors Mini Reviews in Medicinal Chemistry 5 2005 619 630
7. E.D. French, K. Dillon, and X. Wu Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra Neuroreport 8 1997 649 652
8. M. Garcia-Arencibia, S. Gonzalez, L.E. de, J.A. Ramos, R. Mechoulam, and J. Fernandez-Ruiz Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties Brain Research 1134 2007 162 170
9. G. Gille, S.T. Hung, H. Reichmann, and W.-D. Rausch Oxidative stress to dopaminergic neurons as models of Parkinson's disease Annals of the New York Academy of Sciences 1018 2004 533 540
10. A. Giuffrida, L.H. Parsons, T.M. Kerr, F. Rodriguez de Fonseca, M. Navarro, and D. Piomelli Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nature Neuroscience 2 1999 358 363
11. A.J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink Cannabidiol and (-)delta(9)-tetrahydrocannabinol are neuroprotective antioxidants Proceedings of the National Academy of Sciences of the United States of America 95 1998 8268 8273
12. R.D. Hosking, and J.P. Zajicek Therapeutic potential of cannabis in pain medicine British Journal of Anaesthesia 101 2008 59 68
13. Y. Huang, L. Cheung, D. Rowe, and G. Halliday Genetic contributions to Parkinson's disease Brain Research Reviews 46 2004 44 70
14. T. Iuvone, G. Esposito, D. De Filippis, T. Bisogno, S. Petrosino, C. Scuderi, V. Di Marzo, and L. Steardo Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro Journal of Molecular Medicine 85 2007 1379 1392
15. M. Kessiova, A. Alexandrova, A. Georgieva, M. Kirkova, and S. Todorov In vitro effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain Pharmacological Reports 58 2006 870 875
16. S.R. Kim, D.Y. Lee, E.S. Chung, U.T. Oh, S.U. Kim, and B.K. Jin Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro Journal of Neuroscience 25 2005 662 671
17. S. Kuzuhara, H. Mori, N. Izumiyama, M. Yoshimura, and Y. Ihara Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study Acta Neuropathologica 75 1988 345 353
18. D. Marcellino, P. Carriba, M. Filip, A. Borgkvist, M. Frankowska, I. Bellido, S. Tanganelli, C.E. Muller, G. Fisone, C. Lluis, L.F. Agnati, R. Franco, and K. Fuxe Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis Neuropharmacology 54 2008 815 823
19. S. Marinelli, V. Di Marzo, F. Florenzano, F. Fezza, M.T. Viscomi, M. van der Stelt, G. Bernardi, M. Molinari, M. Maccarrone, and N.B. Mercuri N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors Neuropsychopharmacology 32 2007 298 308
20. L.A. Matsuda, T.I. Bonner, and S.J. Lolait Localization of cannabinoid receptor mRNA in rat brain Journal of Comparative Neurology 327 1993 535 550
21. V. Mediavilla, M. Jonquera, I. Schmid-Slembrouck, and A. Soldati Decimal code for growth stages of hemp (Cannabis sativa L.) Journal of Industrial Hemp Association 5 1998 68 74
22. C.W. Olanow, and W.G. Tatton Etiology and pathogenesis of Parkinson's disease Annual Review of Neuroscience 22 1999 123 144
23. M.S. Pollanen, D.W. Dickson, and C. Bergeron Pathology and biology of the Lewy body Journal of Neuropathology and Experimental Neurology 52 1993 183 191
24. M.H. Polymeropoulos, J.J. Higgins, L.I. Golbe, W.G. Johnson, S.E. Ide, G. Di Iorio, G. Sanges, E.S. Stenroos, L.T. Pho, A.A. Schaffer, A.M. Lazzarini, R.L. Nussbaum, and R.C. Duvoisin Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 Science 274 1996 1197 1199
25. K. Radad, R. Moldzio, M. Taha, and W.-D. Rausch Thymoquinone protects dopaminergic neurons against MPP(+) and rotenone Phytotherapy Research 23 2009 696 700
26. F. Rodriguez de Fonseca, I. del Arco, F.J. Bermudez-Silva, A. Bilbao, A. Cippitelli, and M. Navarro The endocannabinoid system: physiology and pharmacology Alcohol and Alcoholism 40 2005 2 14
27. K.A. Sieradzan, S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study Neurology 57 2001 2108 2111
28. M. van der Stelt, S.H. Fox, M. Hill, A.R. Crossman, S. Petrosino, V. Di Marzo, and J.M. Brotchie A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease FASEB Journal 19 2005 1140 1142